December 13, 2016
Astellas Pharma said on December 12 that its European unit will transfer the exclusive rights for Qutenza (capsaicin), a patch treatment for peripheral neuropathic pain, in Europe, Middle East, and Africa to Germany’s Grünenthal. Qutenza was developed by California-based NeurogesX...read more